Wei Zou
Genentech · 62 works · 8,718 citations · h-index 24
Top works
- Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
- Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC
- Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab
- Atezolizumab, an Anti–Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study
- OA20.01 Tumor Mutation Burden (TMB) is Associated with Improved Efficacy of Atezolizumab in 1L and 2L+ NSCLC Patients
- Updated survival and biomarker analyses of a randomized phase II study of atezolizumab vs docetaxel in 2L/3L NSCLC (POPLAR).
- IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC
- Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti–PD-L1)
- ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer
- Tumor mutation load assessed by FoundationOne (FM1) is associated with improved efficacy of atezolizumab (atezo) in patients with advanced NSCLC
- Intratumoral plasma cells predict outcomes to PD-L1 blockade in non-small cell lung cancer
- MA 05.09 Pre-Existing Immunity Measured by Teff Gene Expression in Tumor Tissue is Associated with Atezolizumad Efficacy in NSCLC
- Blood-based biomarkers for cancer immunotherapy: Tumor mutational burden in blood (bTMB) is associated with improved atezolizumab (atezo) efficacy in 2L+ NSCLC (POPLAR and OAK)
- A longitudinal circulating tumor DNA-based model associated with survival in metastatic non-small-cell lung cancer
- Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in KRAS- mutated non-small cell lung cancer with STK11 , KEAP1, or TP53 comutations: subgroup results from the phase III IMpower150 trial
- Intratumoral CD103+ CD8+ T cells predict response to PD-L1 blockade
- Clonal Hematopoiesis in Late-Stage Non–Small-Cell Lung Cancer and Its Impact on Targeted Panel Next-Generation Sequencing
- Cell-autonomous immune gene expression is repressed in pulmonary neuroendocrine cells and small cell lung cancer
- Tumor Dynamic Model-Based Decision Support for Phase Ib/II Combination Studies: A Retrospective Assessment Based on Resampling of the Phase III Study IMpower150
- ctDNA Predicts Overall Survival in Patients With NSCLC Treated With PD-L1 Blockade or With Chemotherapy